secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001104659-23-037370
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharmaceuticals secures $125M financing from RTW for etripamil PSVT program
--------------------------------------------------------------------------------

- $50M in 6.0% convertible senior notes due 2029, convertible at $5.23/share (50% premium over VWAP).
- $75M non-dilutive synthetic royalty commitment on US net sales of etripamil, subject to FDA approval.
- Combined with $64.6M year-end cash, expected to fund operations into mid-2025 including NDA submission and PSVT launch.
- NDA submission for etripamil in paroxysmal supraventricular tachycardia planned for Q3 2023.
- RTW receives tiered royalty rates (high to low single digits) based on annual sales thresholds; rate steps up if thresholds missed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923037370/0001104659-23-037370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923037370/tm2310615d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-037370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer